Our data suggest that reinstating low-levels of FMRP may be sufficient for alleviating certain symptoms – perhaps useful knowledge if technical issues limit the amount of re-instatement of FMRP in certain cell types or if it is desired to avoid over-expression in existing FMRP-positive cells in mosaic FXS individuals. This evidence concerns the gene FMR1 and fragile X syndrome.